The present invention relates to a process for the purification of olanzapine, characterized in that said process comprises at least the following steps:
(A) providing a solution of olanzapine in at least one organic solvent,
(B) treating the solution obtained in step (A) with at least one non-acidic oxide adsorbent, and
(C) removing the said non-acidic oxide adsorbent from the solution obtained in step (B), in order to obtain a solution of olanzapine in a pure form,
to a mixture comprising olanzapine and at least one addition product of methylene chloride and olanzapine in an amount of 10 to 280 ppm, to a pharmaceutical formulation, to the use of said mixture and to a method of treating mental diseases and conditions, which comprises administering a therapeutically effective amount of said mixture in conjunction with a pharmaceutically acceptable diluent or carrier.
本发明涉及一种
奥氮平的纯化过程,其特征在于该过程至少包括以下步骤:(A)在至少一种有机溶剂中提供
奥氮平的溶液,(B)用至少一种非酸性氧化物吸附剂处理步骤(A)中得到的溶液,以及(C)从步骤(B)中得到的溶液中去除所述非酸性氧化物吸附剂,以获得纯净形式的
奥氮平溶液,以及包括
奥氮平和至少一种
氯甲烷和
奥氮平的加成产物的混合物,其中
氯甲烷和
奥氮平的含量为10至280 ppm,以及药物配方、所述混合物的使用以及治疗精神疾病和症状的方法,该方法包括与药学上可接受的稀释剂或载体一起给予所述混合物的治疗有效量。